Building a pipeline to treat previously unreachable diseases

Our Pipeline

PYC Therapeutics is combining our proprietary CPP technology with world-leading expertise in ASOs to create a pipeline of highly precise, safe, and effective combination drugs.

Our initial focus is a program of drugs targeting Inherited Retinal Disease, including Retinitis Pigmentosa; the leading cause of childhood blindness.

Program

discovery > pre-clinical > clinical
Ocular
pipeline Lead program - Retinitis Pigmentosa
pipeline Inherited retinal disease
Other Areas
pipeline Neuro-degenerative
pipeline Liver disease

As we continue to prove and refine our technology we intend to expand our pipeline to include other disease indication and therapeutic areas including genetic neurodegenerative and liver diseases.